The Uromigos

401 Épisodes

1. Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer

   Publié: 21/03/2022
2. Episode 162: Debate - Adjuvant nivolumab for bladder cancer

   Publié: 14/03/2022
3. Episode 161: Platinum eligibility in urothelial cancer

   Publié: 07/03/2022
4. Episode 160: APCCC - PMSA PET as a diagnostic

   Publié: 28/02/2022
5. Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer

   Publié: 19/02/2022
6. Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer

   Publié: 19/02/2022
7. Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer

   Publié: 18/02/2022
8. Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer

   Publié: 18/02/2022
9. Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC

   Publié: 17/02/2022
10. Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer

    Publié: 17/02/2022
11. Episode 153: Overview of PARP inhibition in prostate cancer

    Publié: 10/02/2022
12. Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging

    Publié: 07/02/2022
13. Episode 151: Bladder Cancer ESMO Guidelines update

    Publié: 31/01/2022
14. Episode 150: Comparing the quality of life data in renal trials

    Publié: 24/01/2022
15. Episode 149: Treatment-free survival for ipilimumab and nivolumab

    Publié: 28/12/2021
16. Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer

    Publié: 21/12/2021
17. Episode 147: Renal Cancer Christmas Special

    Publié: 17/12/2021
18. Episode 146: Bladder Cancer Christmas Special

    Publié: 13/12/2021
19. Episode 145: Prostate Cancer Christmas Special

    Publié: 06/12/2021
20. Episode 144: Pembrolizumab for bladder cancer

    Publié: 02/12/2021